Monitoring Disease in Lupus

监测狼疮疾病

• 批准号: 10352313
• 负责人: CHANDRA MOHAN
• 金额: $ 53.66万
• 依托单位: UNIVERSITY OF HOUSTON
• 依托单位国家: 美国
• 财政年份: 2019
• 资助国家: 美国
• 起止时间: 2019-03-08 至 2024-02-29
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10352313
• 关键词: Biological Markers; Clinical; Clinical Trials; Cohort Studies; Cyclophosphamide; Diagnostic; Disease; Disease Management; Disease Progression; Early Diagnosis; Exhibits; Goals; Gold; Histologic; Inflammation; Kidney; Kidney Diseases; Lupus; Lupus Nephritis; Mind; Monitor; Morbidity - disease rate; Neoadjuvant Therapy; Organ; Outcome; Patients; Prediction of Response to Therapy; Prognostic Marker; Proteins; Proteomics; Renal function; Serum; Severity of illness; Specificity; Systemic Lupus Erythematosus; Time; Urine; base; body system; candidate marker; diagnosis standard; diagnostic biomarker; end stage disease; improved; indexing; kidney biopsy; mortality; novel marker; predictive marker; protein biomarkers; screening; systemic autoimmune disease; therapeutic target; tool; treatment response

Lupus is a systemic autoimmune disease resulting in inflammation in multiple organ systems. The disease course is very variable and unpredictable. There is a definite clinical need for better biomarkers for monitoring this disease, particularly renal disease. The current tools available for monitoring lupus and end-organ involvement are not optimal. More reliable tools that detect early disease are warranted. Early detection and prompt treatment can have significant impact on morbidity and disease course. There is also a need for better biomarkers that can be used to assess treatment response in clinical trials. Our completed studies using a couple of targeted proteomic platforms have uncovered several serum or urine proteins that are elevated in lupus patients with elevated SLE disease activity index. From our completed studies, and newly proposed targeted proteomic screens, we will assemble a panel of about 40 serum or urine biomarkers. We will ascertain if these novel biomarkers have the potential to identify lupus patients with active renal disease, monitor disease activity serially, predict treatment response or project long-term outcome in these patients. Besides their biomarker potential, the protein markers examined in this proposal may also constitute therapeutic targets as they exhibit a variety of interesting functional attributes. Better non-invasive biomarkers can significantly improve disease management in patients with lupus nephritis.

狼疮是一种导致多器官系统炎症的全身性自身免疫性疾病。疾病 当然是非常多变和不可预测的。有一个明确的临床需要更好的生物标志物监测 这种疾病，尤其是肾病。目前可用于监测狼疮和终末器官的工具 参与不是最佳的。需要更可靠的工具来检测早期疾病。早期发现和 及时治疗可对发病率和病程产生重大影响。还需要更好地 生物标志物，可用于评估临床试验中的治疗反应。我们完成的研究使用了 几个有针对性的蛋白质组学平台已经发现了几种血清或尿蛋白， 狼疮患者的狼疮疾病活动指数升高。从我们完成的研究，和新提出的 有针对性的蛋白质组学筛选，我们将组装一组约40种血清或尿液生物标志物。我们会查明 如果这些新的生物标志物有可能识别患有活动性肾病的狼疮患者， 活动系列，预测治疗反应或项目的长期结果，在这些患者。除了他们 生物标志物的潜力，在这个建议中检查的蛋白质标志物也可以构成治疗靶点， 它们表现出各种有趣的功能属性。更好的非侵入性生物标志物可以显著 狼疮性肾炎的治疗方法